M&A / Deals Cardio biotech Kardigan binds off $400M upsized IPO BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 19, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GSK claims FDA okay for first oral carbapenem antibioticNext: Heart drug biotech Kardigan raises $400m in upscaled IPO Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
